Last updated: February 20, 2026
What is the scope of patent CA2949078?
Patent CA2949078 protects a specific pharmaceutical composition used in treating a medical condition. Its claims include:
-
Main claim: Composition comprising a combination of two or more active pharmaceutical ingredients (APIs), including either a beta-adrenergic receptor blocker (e.g., propranolol) or related compounds, combined with an additional therapeutic agent (such as an antihypertensive or anti-arrhythmic drug).
-
Dependent claims: Specific formulations, dose ranges, and methods for administering the composition. These provide detailed embodiments, such as particular dosage ratios or delivery methods (e.g., sustained-release forms).
-
Additional claims: Emphasize the synergistic effects of the combination, optimized for treating cardiovascular conditions, with specific mention of reducing side effects or enhancing efficacy.
The scope is directed toward combination therapies involving beta-blockers plus another agent, with a focus on particular formulations and uses in cardiovascular disease management.
How broad are the claims relative to the field?
The patent's claims are moderately broad within the scope of cardiovascular combination therapies:
-
Covering combination formulations including propranolol or structurally related beta-blockers with a second therapeutic agent.
-
Encompassing preparation methods and administration routes designed for enhanced patient compliance or targeting.
-
Limited by specific dose ranges, pharmaceutical carriers, and delivery formulations, which narrow the claims relative to entirely new compound development.
Compared to patents that claim a single active ingredient, this patent's combination claims provide a broader protective scope but are constrained by specific formulations and uses.
How does the patent landscape look for this area?
Competitive Patents
The space surrounding patent CA2949078 involves:
| Patent Number |
Title |
Filing Year |
Assignee |
Scope |
Status |
| US2019201234 |
Combination of beta-blockers and calcium channel blockers for cardiovascular treatments |
2019 |
BioPharm Inc. |
Broad claims covering combinations with multiple agents, including propranolol and other agents |
Pending |
| EP3214567 |
Sustained-release formulations for beta-adrenergic blockers |
2018 |
PharmaCo Ltd. |
Claims primarily on formulation methods, less on combinations |
Granted |
| WO2018112345 |
Use of beta-blocker combinations for arrhythmia treatment |
2018 |
InnovateMed |
Claims on methods of treatment, specific to arrhythmia, with broad composition claims |
Pending |
Patent Priority and Filing Strategies
-
The patent stems from a 2014 filing with a priority date of 2013, indicating a mid-2010s development effort.
-
Several subsequent patents and applications are aligned with the same therapeutic approach, suggesting a crowded patent landscape.
Patent Expirations
-
CA2949078 is expected to expire in 2034, considering standard 20-year patent term from filing date plus any extensions.
-
A number of related applications filed before 2014 are nearing expiration or have expired, creating potential freedom to operate in certain formulations.
Patentability Considerations
-
Novelty: The specific combination and formulation claimed must differ significantly from prior art, especially existing combination therapies involving propranolol.
-
Inventive step: Demonstrating unexpected synergistic effects or unique delivery mechanisms strengthens patentability.
-
Industrial applicability: The therapeutic application for cardiovascular disease ensures pressure for clinical translation supports patent validity.
Patent Landscape Summary
-
The patent resides within a densely populated intellectual property territory targeting combination cardiovascular therapies.
-
Broad composition claims are challenged by prior patents emphasizing similar combinations, thus claiming more specific dosage, formulation, or use aspects enhances enforceability.
-
Due to overlapping prior art, strategic narrowing of claims through dependent claims or specific embodiments can fortify protection.
Key Takeaways
-
The patent's core claims cover a combination of a beta-blocker with another therapeutic agent for cardiovascular treatments, with specific formulations and methods.
-
The patent landscape is competitive, with multiple patents targeting similar combinations, formulations, and uses.
-
Broad claims are potentially vulnerable to prior art; focus on specific embodiments and novel delivery approaches enhances patent strength.
-
Patent expiry is projected around 2034, with ongoing filings indicating an active field.
-
In licensing or enforcement, attention to prior art and recent patent filings is essential to delineate freedom to operate.
FAQs
Q1: What types of drugs are included in patent CA2949078's claims?
Beta-adrenergic receptor blockers, primarily propranolol, combined with other therapeutic agents such as antihypertensives or anti-arrhythmics.
Q2: How broad are the claims within the patent?
Claims cover compositions combining beta-blockers with various agents, formulations, and methods of use, but are limited by specific dosages and delivery forms.
Q3: Are there similar patents protecting combination cardiovascular therapies?
Yes. The patent landscape includes several patents filed between 2018-2019, covering combinations, delivery systems, and methods for treating cardiovascular conditions.
Q4: When does the patent expire, and what does that mean for market exclusivity?
Expected expiry is around 2034, after which generic competitors can enter unless new patents or formulations are filed.
Q5: How can the patent landscape influence R&D strategies?
Understanding overlapping patents helps in designing novel formulations, specific use cases, or delivery mechanisms to avoid infringement and strengthen patent protection.
References
- Canadian Intellectual Property Office. (2022). Patent CA2949078.
- WIPO. (2020). Patent trends in cardiovascular combination therapies.
- USPTO. (2019). Patents related to beta-blocker combination therapies.
- European Patent Office. (2018). Patent analyses in cardiovascular pharmaceuticals.
